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Abstract
To investigate the relationship between the FGF1 oestrogen regulation and the normal/cancer status of breast cells, we
have studied FGF1 17L-oestradiol regulation in normal, transformed and cancerous cells. Normal (NMEC), transformed
(HBL-100) and cancerous (MCF-7, MDA-MB-231) human mammary epithelial cells express different levels of FGF1
mRNAs. Western blot analysis allowed us to characterize FGF1 as an 18 kDa form of this polypeptide. Using a neutralizing
anti-FGF1 antibody we demonstrated that FGF1 is secreted by all mammary cells studied and stimulates their proliferation
in an autocrine manner. We have examined the regulation of FGF1 mRNAs in response to 17L-oestradiol. FGF1 mRNAs
were upregulated in hormone-dependent NMEC but was not upregulated either in hormone-sensitive HBL-100 cells or in the
hormone-dependent cancerous cell line MCF-7. However, enzyme linked immunosorbent assay indicated an increase of
FGF1 protein in NMEC, HBL-100 and MCF-7 cells. We have also examined the 17L-oestradiol regulation of the four
alternatively spliced FGF1 mRNAs: 1.A, 1.B, 1.C and 1.D. Only 1.B transcripts were downregulated by 17L-oestradiol in
normal cells. These results show that 17L-oestradiol regulates FGF1 mRNAs in a cell-specific manner, and that this
regulation may be transcriptional or translational depending on cell phenotype. The specificity of oestradiol effects was
checked using its receptor antagonist tamoxifen. z 1998 Elsevier Science B.V.
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1. Introduction
The control of mammary gland growth is a com-
plex phenomenon which includes the concerted ac-
tion of growth factors and hormones [1]. Epidermal
growth factor (EGF) [2], transforming growth factor
K (TGFK) [3], ¢broblast growth factor 1 (FGF1)
(acidic FGF) [4], FGF2 (basic FGF) [5] and insu-
lin-like growth factor 1 (IGF-I) [6] have been re-
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Abbreviations: EGF, epidermal growth factor; ELISA, en-
zyme linked immunosorbent assay; FCS, fetal calf serum;
FGF, ¢broblast growth factor; IGF, insulin-like growth factor;
NMEC, normal mammary epithelial cell ; TGFK, transforming
growth factor K ; TGFL, transforming growth factor L
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ported to be growth promoting factors for mammary
cells. The mammary gland produces these growth
factors [3^11]. Moreover, the mammary gland epithe-
lial component secretes an autocrine growth factor
known as MDGF-I for mammary derived growth
factor 1 [12]. The growth of normal mammary tissue
is limited by secreted growth inhibitors such as
TGFL [13], mammastatin [14] and MDGI (mammary
derived growth inhibitor) [15]. It has been demon-
strated that progesterone and prolactin could directly
stimulate the in vitro proliferation of mammary cells
while oestrogens would not behave as mitogenic fac-
tors for these cells [16,17]. However, oestrogens play
a key role in mammary gland development since they
enhance prolactin secretion, induce progesterone re-
ceptors [16], stimulate EGF/EGF receptor [18] and
TGFK/TGFK receptor [19] production. Monaham et
al. [20] convincingly argued that oestrogens could
also sensitize the epithelial tissue to MDGF-I.
The loss of growth control is one of the numerous
features of cancer cells. In breast cancer epithelial
cells, it has been shown that EGF [21], TGFK [22]
and IGF-II [23] were upregulated by oestrogens
while TGFL factors [24,25] were downregulated by
these hormones. The role of oestrogens in the regu-
lation of FGF production in mammary epithelial
cells is not yet studied. Nevertheless, FGFs seem to
be important factors in breast carcinogenesis. It is
known that normal and cancer breast epithelial cells
possess high and low a⁄nity receptors for FGFs [26^
32] and that their proliferation is in£uenced by these
factors [26,33^35]. In particular, exogenous FGF1
and FGF2 stimulate the proliferation of oestrogen
receptor-positive MCF-7 cells [26,34], in£uence
scarcely the growth of the oestrogen receptor-nega-
tive MDA-MB-231 cells [26] and inhibit the prolifer-
ation of the oestrogen receptor-positive MDA-MB-
134 cells that present FGF receptor overexpression
[36]. Expression of FGF1 mRNA was detected in
several types of breast epithelial cells such as the
normal mammary epithelial cells (NMEC), the trans-
formed non-tumorigenic cell line (HBL-100) [37] and
cancer cell lines MDA-MB-231, BT-20 and MCF-7
[31,37]. Other well characterized cancer mammary
cell lines such as the hormone-independent BT474
and the hormone-dependent T47D and ZR75.1 do
not express FGF1 mRNAs [31]. Expression of
FGF2 mRNA was detected in all these cells except
MCF-7 [37^40]. Moreover, we demonstrated previ-
ously that the breast cancer cell line MDA-MB-231
produces FGF2 protein that is involved in an auto-
crine loop of growth stimulation [41].
In the present paper, we have investigated the pro-
duction of FGF1 mRNAs and protein in human
hormone-dependent epithelial normal (NMEC),
transformed (HBL-100), and cancerous (MCF-7)
breast cells. The presence and the oestradiol regula-
tion of FGF1 protein in these cells was demonstrated
by immunological methods. Moreover, we demon-
strated the autocrine stimulation of these cells by
FGF1 using anti-FGF1 neutralizing antibody. The
two hormone-independent BT20 and MDA-MB-231
cell lines were analysed for FGF1 mRNA expression.
As BT-20 cells express very low levels of FGF1 [37],
MDA-MB-231 cells were preferentially used as hor-
mone-independent cell line. The expression and oes-
tradiol regulation of FGF1 mRNAs (coding tran-
scripts including the four alternatively spliced
transcripts 1.A, 1.B, 1.C and 1.D generated by alter-
native splicing of the four di¡erent 5P non-coding
exons to the ¢rst coding exon of FGF1 human
gene [42^46]) in all these mammary epithelial cells
cultured in the absence of serum and of phenol red
were analysed by RT-PCR. The experiments per-
formed to investigate the relationship between the
oestrogen regulation of this molecule and the nor-
mal/cancer status of human mammary cells indicated
a cell-speci¢c 17L-oestradiol control.
2. Materials and methods
Eagle’s minimal essential medium Earle’s salt,
Dulbecco’s modi¢ed Eagle’s, Ham’s F12 media,
HEPES, sodium bicarbonate, fetal calf serum
(FCS), non-essential amino acids, L-glutamine, anti-
biotics and 1 U Taq polymerase were purchased
from Eurobio (Les Ullis, France). Insulin was from
Organon (Serifontaine, France). Cortisol, cholera
toxin, EGF, FCS Ca2-chelated by Chelex 100, bo-
vine serum albumin (BSA), phenylmethylsulfonyl £u-
oride (PMSF), leupeptin, pepstatin, biotin goat anti-
rabbit immunoglobulins, extravidin-peroxidase con-
jugate, 3-amino-9-ethylcarbazole (AEC) solution,
heparin, phenol red-free medium, bovine serum al-
bumin fraction V, human holotransferrin, 17L-oes-
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tradiol water-soluble (E 4389) and tamoxifen were
from Sigma (Saint-Quentin-Fallavier, France).
Heparin-Sepharose was from Pharmacia (Uppsala,
Sweden). Triton X-100 and BCA kit were from
Pierce (Rockford, IL, USA). [methyl-3H]Thymidine
(50 Ci/mmol) was from ICN (France). Biotin-strep-
tavidin ampli¢cation kit, donkey biotinylated anti-
IgG, streptavidin-horseradish peroxidase conjugate
and ECL Western blotting detection reagents were
purchased from Amersham International (Amer-
sham, Bucks, UK). For enzyme linked immunosorb-
ent assay (ELISA) and Western blot analysis, rabbit
polyclonal antibody directed against human re-
combinant FGF1 [47] was a generous gift from
Dr. Y. Courtois (U450, INSERM, Paris, France).
The mouse IgM monoclonal FGF1 neutralizing
antibody 47K was a generous gift from Dr. G. H.
Sato (Lake Placid, USA) [48].The mouse IgM
monoclonal FGF1 non-neutralizing antibody 5G9
was a generous gift from Dr. Hendry (Canberra,
Australia). We produced the anti-NGF-like mouse
monoclonal IgM antibody B3. 300 U Mo MMLV
reverse transcriptase was from Gibco/BRL (Eragny,
France). PCR oligonucleotide primers, oligonucleo-
tide and polynucleotide probes are presented in
Tables 1 and 2..
2.1. Cell culture
The human breast cancer cells MCF-7 and MDA-
MB-231 are two established carcinoma cell lines de-
rived from the pleural e¡usion of breast cancer pa-
tients [49,50]. HBL-100 is a human breast epithelial
cell line [51] reportedly non-tumorigenic in nude
mice, but which is able to form colonies in soft
agar. The normal human mammary epithelial cells
(NMEC) were obtained from female mammoplasty
reduction. The epithelial phenotype of the normal
cells was checked by immunocytochemistry using
anti-vimentine and anti-cytokeratine C14 and C18.
NMEC did not express vimentine but express the
cytokeratines. MCF-7, MDA-MB-231 and HBL-
100 cell lines were grown in Eagle’s minimal essential
medium Earle’s salt containing 20 mM HEPES,
0.22% sodium bicarbonate, 10% fetal calf serum,
1% non-essential amino acids, 2 mM L-glutamine,
5 Wg/ml insulin and antibiotics (40 Wg/ml streptomy-
cin; 40 IU/ml penicillin). The NMEC were obtained
according to the techniques described by Soule and
McGrath [52]. Epithelial cells were seeded in 145 mm
Petri dishes in a medium made of Dulbecco’s modi-
¢ed Eagle’s and Ham’s F12 media (v/v), containing
40 WM CaCl2, 20 mM NaOH, 0.22% sodium bicar-
bonate, 2 mM L-glutamine, 10 Wg/ml insulin, 2 ng/ml
cortisol, 40 IU/ml penicillin, 40 Wg/ml streptomycin,
4 Wg/ml gentamicin, 0.25 ng/ml fungizon, 100 ng/ml
cholera toxin, 2 ng/ml EGF, and supplemented with
5% FCS Ca2-chelated by Chelex 100 [53]. Cells were
then incubated at 37‡C in 5% C02 :95% air humi-
di¢ed atmosphere.
Table 1
RT-PCR ampli¢cations (speci¢city, RT-PCR primers, ampli¢ed fragment, probes)
RT-PCR speci¢city RT-PCR primers Ampli¢ed fragment (bp) Hybridization primers or cDNA
FGF1 COD COD Rev/COD For 135 FGF1 cDNA
FGF1 E1.A E1P/EAP 372 EAH
FGF1 E1.B E1P/EBP 319 EBH
FGF1 E1.C E1P/ECP 256 ECH
FGF1 E1.D E1P/EDP 213 E1H
NR NR Rev/NR For 75 NR cDNA
This table summarizes the primers used to amplify the di¡erent FGF1 cDNAs in RT-PCR assays, the length of the ampli¢ed frag-
ments and the primers used in Southern blot hybridization. Total codant FGF1 (FGF1 COD) and nitrate reductase (NR) mRNAs,
which were ¢rst reverse transcribed to FGF1 COD and NR cDNAs, were ampli¢ed using codant reverse and codant forward primers
(COD Rev/COD For) and nitrate reductase reverse and forward primers (NR Rev/NR For respectively). The four alternatively spliced
FGF1 mRNAs (FGF1 E1.A, FGF1 E1.B, FGF1 E1.C, FGF1 E1.D) were ampli¢ed using the same antisense E1P primer and di¡er-
ent sense primers called EAP, EBP, ECP, EDP. FGF1 and nitrate reductase cDNAs were detected with speci¢c FGF1 and NR
cDNA probes respectively. The cDNAs corresponding to the alternatively spliced FGF1 mRNAs were hybridized with speci¢c oligo-
nucleotide primers (EAH, EBH, ECH, EDH).
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2.2. Preparation of cellular extracts and heparin
a⁄nity chromatography
For ELISA, the cells were washed with PBS and
incubated with 50 Wg/ml heparin (15 min, 37‡C) to
remove membrane ¢xed FGFs. The supernatant of
the cell homogenate was loaded at 4‡C onto a hep-
arin-Sepharose column (1.6U20 cm, bed volume =
10 ml) pre-equilibrated with 50 mM phosphate
bu¡er (PB) containing 150 mM NaCl, pH 7.5. In
these conditions the capacity of the heparin-Sephar-
ose column was not exceeded by the quantity of
FGF1 to be bound; no FGF1 was immuno-
detected in the unbound fraction. Bound proteins
were eluted with increasing concentrations of NaCl
(0.5, 1.15, 2 and 3 M) in PB. ELISA realized with
FGF1 antibody allowed to know that the whole
FGF1 fraction was eluted in the presence of 1.15 M
NaCl.
For Western blot analysis, NMEC, HBL-100,
MCF-7 and MDA-MB-231 cells were lysed in PBS
pH 7.5 containing 2 M NaCl, 0.1% Triton X-100 and
antiproteases (1 mM PMSF, 1 Wg/ml leupeptin,
1 Wg/ml pepstatin). The protein concentration of
the lysates was determined using a BCA kit. Cell
lysate proteins (600 Wg) were incubated with 100 Wl
of heparin-Sepharose in PBS 0.6 M NaCl. After
overnight shaking at 4‡C, the heparin-Sepharose
was washed twice with the binding bu¡er and then
the heparin-binding proteins eluted in 100 Wl of
Laemmli bu¡er.
2.3. ELISA
Aliquots of fractions (100 Wl) from heparin a⁄nity
chromatography were coated overnight at 4‡C in 96-
well plates (Falcon). Blockage of free protein-binding
sites in wells was performed with 2% bovine serum
albumin in PBS (0.01 M phosphate bu¡er, 0.15 M
NaCl, pH 7.5, 0.05% Tween 20) (2 h, room temper-
ature). The wells were then treated with rabbit anti-
sera raised against human recombinant FGF1. The
antigen-antibody complex was detected by the bio-
tin-streptavidin ampli¢cation kit according to the
manufacturer’s instructions. In controls, the wells
were coated with recombinant FGF1 (2.5 ng/100 Wl
PBS) or the primary antibody was replaced by pre-
immune rabbit serum.
2.4. FGF1 expression analysis by Western blot
Ten micrograms of heparin-binding proteins were
electrophoresed on 18% polyacrylamide gel (SDS-
PAGE) and then electrotransferred to nitrocellulose
membrane (Optitron BA-S 83, Schleicher and
Schuell). The blotted proteins were incubated (1 h,
37‡C) with rabbit polyclonal FGF1 antibody (dilu-
tion 1/500) in 150 mM NaCl, 100 mM Na-phosphate
bu¡er (pH 7.6) containing 2% BSA. The membrane
was washed 3 times (15 min) in the aforementioned
bu¡er, incubated (1 h, 37‡C) with a donkey bio-
tinylated anti-IgG (dilution 1/400) and then with
streptavidin-horseradish peroxidase conjugate (dilu-
tion 1/400). The immunoreactive proteins were ¢nally
revealed with ECL Western blotting detection re-
agents according to the manufacturer’s suggested
protocol. Controls were performed with electropho-
resed recombinant FGF1, or the primary antibody
was replaced by preimmune rabbit serum.
2.5. Mitogenic activity of endogenous FGF1
FGF1-like activity in NMEC, HBL-100, MCF-7
and MDA-MB-231 conditioned media was measured
by assays on these cell lines themselves in the pres-
ence of monoclonal neutralizing anti-FGF1 antibody
(47K). The cells cultured in complete medium (10%
FCS) in 75 cm2 £asks were passaged and washed
twice with serum-free medium. Then cells were
seeded in 24-well plates in serum-free medium
(20 000 cells per 250 Wl of medium per well) contain-
ing the 47K neutralizing anti-FGF1 antibody (0, 4,
16 or 32 Wg/ml). The cells were maintained in this
antibody supplemented medium for 68 h. After 64 h,
1 WCi of [methyl-3H]thymidine (50 Ci/mmol) was
added to each well (4 h, 37‡C). The cells were then
rinsed with PBS, treated with cold 5% trichloroacetic
acid (45 min, 4‡C), rinsed 3 times with water and
solubilized with 0.3 M NaOH (1 h, 37‡C). The
[3H]thymidine uptake by cells of each well was meas-
ured with a L-counter (LKB Wallac). Each result is
the average of six assays. The controls were per-
formed as cell cultures incubated in serum-free me-
dium without neutralizing antibody or with the non-
neutralizing anti-FGF1 mouse monoclonal IgM anti-
body 5G9, or with anti-NGF-like mouse monoclonal
IgM antibody B3 and also as cells incubated with
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16 Wg/ml of 47K neutralizing antibody and 25 ng/ml
of standard FGF1.
2.6. 17L-Oestradiol regulation assay
Cells were seeded at low density in complete me-
dium. When cells reached about 50% con£uence,
they were washed twice with PBS and the medium
was replaced by phenol red-free medium for 48 h,
changed every 12 h, in order to eliminate residual
e¡ects of oestrogen present in the standard media.
The phenol red-free medium was supplemented
with 2 mg/ml bovine serum albumin fraction V,
10 Wg/ml human holotransferrin, 5 Wg/ml insulin,
2 mM glutamine and 2 mM non-essential amino
acids. Cells were treated by 1038 M 17L-oestradiol
water-soluble with or without 1036 M tamoxifen for
24 h. In the control experiment, the 17L-oestradiol
was replaced by sterile water and tamoxifen by ab-
solute ethanol.
2.7. RNA isolation
Total RNA was isolated from subcon£uent grow-
ing cells under conditions using the guanidium iso-
thiocyanate and CsCl gradient method [54]. The
quality of RNA was veri¢ed by agarose gel electro-
phoresis and ethidium bromide staining. RNA sam-
ples were quanti¢ed by measuring their optical den-
sity at 260 nm.
2.8. Reverse transcription reaction
Complementary DNAs were synthesized from 1 Wg
of total RNA and 170 pg tobacco leaf nitrate reduc-
tase (NR) transcripts (U450, INSERM, Paris,
France). RNAs were annealed (2 h at 42‡C) to
2.5 WM random hexanucleotide primers in 30 Wl of
50 mM Tris-HCl pH 8.9, 3 mM MgCl2, 75 mM KCl,
300 U Mo MMLV reverse transcriptase. The reac-
tion was stopped by heating at 95‡C for 5 min. NR
transcripts were added to the cellular RNA, reverse
transcribed and coampli¢ed to ensure that RT-PCR
e⁄ciency remained constant in the di¡erent samples
of each experiment.
2.9. PCR ampli¢cation
After heat inactivation, 3 Wl from the cDNA reac-
tion was ampli¢ed in a ¢nal volume of 100 Wl of
50 mM Tris-HCl pH 8.9, 7 mM MgCl2, 50 mM
KCl, 15 mM ammonium sulphate, 0.17 mg/ml
BSA, 1 mM of dNTP mix, 15 pmoles of FGF1
and nitrate reductase (NR) speci¢c primers, and 1 U
Taq polymerase. The ampli¢cation conditions were
as follows: denaturation at 92‡C for 30 s, annealing
Table 2
Sequence and location of the di¡erent primers used in RT-PCR assays
Speci¢city Primers Sequences (5PC3P) Positiona Orientation
FGF1 COD For AAGCCCGTCGGTGTCCATGG 261 to 242 antisense
COD Rev GATGGCACAGTGGATGGGAC 127 to 146 sense
E1P GTCCCATCCACTGTGCCATC 146 to 127 antisense
PCR primers EAP ATCCCACAGCCTTCGCTCCA 3226 to 3207 sense
EBP CACTCAGAGCTGCAGTAGCCT 3173 to 3153 sense
ECP ATTCCTTAGTGAGTGAGTTCAC 3110 to 389 sense
EDP TGGCAGCAGCACAATGTTTGGGCTA 367 to 343 sense
Probes E1H ATGGCTGAAGGGGAAATCACC 1 to 21 sense
EAH AATCAGGGCATCGCCTCCTTT 3202 to 3182 sense
EBH CTACTCTGAGAAGAAGACACC 3133 to 3113 sense
ECH CACTTCTGCAGGGAAGCCAGC 368 to 348 sense
NR NR For GCTGGATCCATTGCAAATTCC 284 to 264 antisense
NR Rev AGGAGCTGATGTGTTGCCCGG 207 to 227 sense
This table summarizes the sequence and the position to the translation start codon ATG of the primers used in RT-PCR assays and
of the oligoprobes used in Southern blot hybridization for FGF1 and nitrate reductase cDNAs.
aThe numerations are all initiated to the translation start codon ATG.
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at 62‡C for 1 min, extension at 72‡C for 30 s. In
preliminary experiments, the level of FGF1 mRNA
in the di¡erent cell lines was tested by RT-PCR after
20^40 cycles of ampli¢cation (denaturation: 92‡C for
30 s; annealing: 62‡C for 1 min; extension: 72‡C for
30 s), and the linear exponential FGF1 ampli¢cation
phase determined. To ensure that the ampli¢cation
was in the exponential phase, aliquots were with-
drawn at three di¡erent cycles and analysed. For
FGF1 ampli¢cation, the oligomers were chosen in
di¡erent exons as described in Scheme 1. The fea-
tures of the RT-PCR primers (FGF1 COD Rev,
FGF1 COD For, E1P, EAP, EBP, ECP, EDP) are
summarized in Table 2. To assess the RT-PCR e⁄-
ciency, reverse transcribed tobacco nitrate reductase
transcripts were added to the FGF1 cDNA reaction,
and coampli¢ed. Non-reverse transcribed RNA was
also submitted to the PCR ampli¢cation steps and
used as a negative control for DNA contamination.
2.10. Southern blotting and hybridization
The ampli¢ed fragments were separated in a 10%
polyacrylamide gel which was then denatured in 200
mM NaOH, 600 mM NaCl bu¡er for 20 min. The
gel was washed in water and rinsed 3 times in 150
mM citrate bu¡er. The fragments were electroblotted
onto Hybond N membrane (Amersham France)
which was activated in methanol for 3 min and
washed in citrate bu¡er. The electroblotting was ef-
fected at 0.8 mA/cm2 for 2 h in citrate bu¡er. The
membrane containing cDNA ampli¢ed fragments of
coding FGF1 and nitrate reductase was hybridized
with speci¢c cDNA polynucleotide probes [32P]dCTP
radioactively labelled by the random-primed synthe-
sis method [55]. The membrane containing ampli¢ed
cDNA of the four spliced FGF1 transcripts was hy-
bridized with speci¢c oligonucleotide probes (Table
2: EAH, EBH, ECH, E1H), which were [Q-32P]ATP,
radioactively labelled by kination. The membrane
was then washed in 1USSC, 0.1% SDS at 55‡C if
hybridized with oligonucleotide probes, or in the
same bu¡er at 65‡C if hybridized with polynucleotide
probes. The membrane was exposed to X-OMAT
AR5-ray ¢lm (Kodak).
Even if the PCR primers were speci¢c and no more
than one band is obtained in the polyacrylamide gel
electrophoresis of PCR products, an additional layer
of speci¢city was provided by the probes. The probes
were applied to the blots simultaneously as FGF1
with nitrate reductase, exon B with exon D, exon
A with exon C.
2.11. Statistical analysis
Variance is expressed as the mean þ S.D. of the
Scheme 1. Scheme of the di¡erent human FGF1 mRNAs (studied in this paper). EA, EB, EC, and ED represent the non-coding
exons A, B, C and D of human FGF1 gene. I1, I2 and I3 represent the three introns of human FGF1 gene that are on position 334,
170 and 273 relative to the translation initiation codon ATG. Rev COD and For COD corresponding respectively to Reverse Codant
and Forward Codant. FGF1 primers were chosen to amplify the total FGF1 codant mRNAs.E1P was the antisense oligonucleotide
used to amplify all the four alternatively spliced FGF1 mRNAs containing the exon A, or B, or C, or D. The EAP, EBP, ECP and
EDP were the sense primers used to amplify these FGF1 mRNAs. For the hybridization, probes were chosen as presented in the
scheme (EAH, EBH, ECH, EDH). The arrow indicates the orientation and the approximate position of the oligonucleotides.
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average of each point for the number of experiments
indicated and signi¢cance (P6 0.05) determined by
paired or unpaired Student’s t-test as appropriate.
3. Results
We will report here the results obtained on the
production of FGF1 and its regulation by oestradiol
in di¡erent well characterized epithelial breast cells.
Normal cells (NMEC) were obtained from mammo-
plasty reduction and their epithelial phenotype was
checked using anti-vimentine and anti-cytokeratine
C14 and C18 antibodies. NMEC possess oestrogen
receptors and are hormone-dependent. HBL-100 was
isolated from milk of a healthy woman and trans-
formed by SV40 virus. This cell line is characterized
as non-tumorigenic in nude mice and responsive to
prolactin and oestrogen. MCF-7 and MDA-MB-231
cells form two established carcinoma cell lines de-
rived from pleural e¡usion and which are tumorigen-
ic in nude mice. MCF-7 cells present several features
of di¡erentiated mammary epithelium including the
ability to process oestradiol via cytoplasmic oestro-
gen receptors. MDA-MB-231 is characterized as a
hormone-independent cell line which lacks oestrogen
receptor.
Controls realized with a range of dilution of re-
combinant FGF1 from 100 pg to 1 Wg/100 Wl allowed
us to know that 100 pg of FGF1 was su⁄cient to be
immunodetected in ELISA and Western blot.
3.1. Immunodetection of FGF1 protein in mammary
epithelial cells
3.1.1. ELISA
Aliquots of conditioned serum-free medium and of
the normal and cancerous cell extract fractions,
eluted in the presence of 1.15 M NaCl from the hep-
arin a⁄nity chromatography, showed immunological
reactivity with the anti-FGF1 speci¢c polyclonal
antibody [47] in an ELISA (Fig. 1).
3.1.2. Western blot
After the puri¢cation of cell extract proteins by
heparin a⁄nity chromatography, the proteins of
non-concentrated extracts were separated by SDS-
PAGE and analysed by Western blot. A main
band, corresponding to about Mr 18 000 protein re-
acting to FGF1 antibody, was observed for NMEC,
transformed HBL-100 and cancerous MDA-MB-231
and MCF-7 cells (Fig. 2). A weaker signal of about
Mr 19 000 was also detectable for HBL-100, MDA-
MB-231 and MCF-7 cells. Recombinant FGF1 used
as control showed the same bands. Moreover, HBL-
100 and MDA-MB-231 cell extracts contain an addi-
tional band of Mr 15 000^16 000 proteins probably
corresponding to degraded forms of FGF1 (Fig. 2).
3.2. Mitogenic activity of endogenous FGF1
In serum-free medium, [methyl-3H]thymidine in-
Fig. 2. Western blot analysis of non concentrated mammary ep-
ithelial cell extracts after heparin-Sepharose chromatography.
Proteins co-migrating with recombinant human FGF1 (rFGF1)
were detected with anti-FGF1 polyclonal antibody in 10 Wg of
fractions of the normal (NMEC), transformed HBL-100 (HBL),
cancerous MCF-7 and MDA-MB-231 (MDA) cell extracts
eluted in the presence of Laemmli bu¡er.
Fig. 1. ELISA analysis of FGF1 protein in breast epithelial
cells. Protein was detected with anti-FGF1 polyclonal antibody
in aliquots (100 Wl) of culture supernatants (S) and of extracts
(CE) (1 M NaCl fraction from heparin-Sepharose chromatogra-
phy) of NMEC, HBL-100, MCF-7 and MDA-MB-231 cells cul-
tured to about 50% con£uence in serum-free and phenol red-
free medium. Control wells coated with 2.5 ng of FGF1 in 100
Wl of PBS presented a mean value of OD at 490 nm of 2.07.
Mean þ S.D. of triplicate determination (P6 0.05). Experi-
ments were repeated two times.
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corporation in MDA-MB-231 cells was greater than
in the other breast cells studied (Fig. 3). The addition
of 47K neutralizing anti-FGF1 antibody to NMEC,
HBL-100, MCF-7 and MDA-MB-231 culture media
reduced signi¢cantly their proliferation in serum-
free medium (Fig. 3). The decrease of [methyl-3H]
thymidine incorporation in the presence of this anti-
body is dose-dependent. At the highest concentration
of the 47K anti-FGF1 antibody used (32 Wg/ml), each
cell line presented a similar level of [methyl-
3H]thymidine incorporation. However, this level cor-
responded to a decrease of approx. 55% in NMEC
and MCF-7 (Fig. 3, NMEC and MCF-7), a 75%
decrease in HBL-100 (Fig. 3, HBL-100) and a 93%
decrease in MDA-MB-231 (Fig. 3, MDA-MB-231)
[methyl-3H]thymidine incorporation. No e¡ect on
proliferation of either normal or cancer cells was
observed when standard FGF1 (25 ng/ml) was simul-
taneously added with anti-FGF1 antibody (Fig. 3).
Control experiments with anti-NGF-like B3 antibody
or with the non-neutralizing anti-FGF1 5G9 anti-
body showed no modi¢cation of normal and cancer-
ous breast epithelial cell proliferation (Fig. 3).
3.3. FGF1 protein and mRNA regulation by oestradiol
in normal and cancerous breast cells
We ¢rst checked by [3H]thymidine incorporation
that the proliferation of normal and MCF-7 cancer-
ous cells was stimulated by 1038 M 17L-oestradiol.
3.3.1. ELISA analysis of FGF1 regulation by
17L-oestradiol
This study was performed on extracts (600 Wg of
total proteins) of normal and cancerous cells grown
in phenol red-free medium alone or supplemented
with 1038 M 17L-oestradiol alone or associated to
1036 M tamoxifen. FGF1 was detected in aliquots
of heparin-Sepharose chromatography fractions.
17L-Oestradiol enhanced the level of FGF1 in
NMEC, HBL-100 and MCF-7 cells. FGF1 protein
level was not modi¢ed in cells cultured in the pres-
Fig. 3. Proliferation of mammary epithelial cells in the presence of neutralizing anti-FGF1 antibody. Normal mammary epithelial cells
(NMEC), transformed (HBL-100) and cancerous MCF-7 and MDA-MB-231 cells were cultured in serum-free medium (0) or with dif-
ferent concentrations of 47K neutralizing anti-FGF1 antibody (47 alpha/well : 1, 4 or 8 Wg/250 Wl). The proliferation was measured by
[3H]thymidine incorporation. Signi¢cant decrease of [3H]thymidine incorporation was observed in presence of anti-FGF1 antibody at
a concentration ranging from 1 to 8 Wg/250 Wl for HBL-100 and MDA-MB-231 cells (P6 0.01) and from 4 to 8 Wg/250 Wl for NMEC
(P6 0.01) and MCF-7 cells (P6 0.02) compared to control (0). When exogenous FGF1 (6.25 ng/250 Wl) was added with the anti-
FGF1 (4 Wg/250 Wl) in the medium, no signi¢cant modi¢cation of [3H]thymidine incorporation was obtained in NMEC, HBL-100,
MCF-7 (P6 0.02) and MDA-MB-231 cells (P6 0.01). Moreover, [3H]thymidine incorporation in mammary epithelial cells (P6 0.01)
cultured in presence of the non neutralizing anti-FGF1 antibody 5G9 (8 Wg/250 Wl) was close to the control (0) incorporation. Anti-
NGF-like antibody B3 (8 Wg/250 Wl) tested only on the highly proliferative MDA-MB-231 cells had also no e¡ect on the
[3H]thymidine incorporation (P6 0.05) compared to the control (0) incorporation. Results are expressed as the mean þ S.D. of tripli-
cate determinations. Similar results were obtained when the experiments were repeated three times.
BBAMCR 14308 8-6-98
I. El Yazidi et al. / Biochimica et Biophysica Acta 1403 (1998) 127^140134
ence of both 17L-oestradiol and its inhibitor (I) ta-
moxifen. No change in levels of FGF1 was induced
in the hormone-independent MDA-MB-231 cells by
17L-oestradiol (Fig. 4).
3.3.2. FGF1 mRNA expression and regulation by
17L-oestradiol
Northern blot analysis was performed on 20 Wg of
total RNAs from HBL-100 transformed cells and
from cancerous cell lines MDA-MB-231 and MCF-
7 to visualize FGF1 mRNAs. No transcript was de-
tected in cancerous cells (data not shown). The level
of these transcripts was too low and prompted us to
use a semi-quantitative assay based on the PCR am-
pli¢cation of FGF1 cDNA.
One microgram of total RNAs isolated from
NMEC, HBL-100, MCF-7 and MDA-MB-231 cell
lines was submitted to RT-PCR assays to analyse
FGF1 mRNA expression and regulation by 17L-oes-
tradiol in normal and cancerous mammary cells cul-
tured in serum-free and red phenol-free medium. In
the absence of 17L-oestradiol and after 30 cycles of
PCR ampli¢cation (exponential phase of PCR),
FGF1 mRNAs were ampli¢ed in NMEC, HBL-100
(Fig. 5A, lane 1) and MDA-MB-231 cell lines (data
not shown) but not in MCF-7 cells. After 40 cycles
of ampli¢cation, FGF1 mRNAs were detected in
MCF-7 and MDA-MB-231 cell lines (Fig. 5B, lane
Fig. 5. RT-PCR analysis of FGF1 mRNA regulation by 17L-oestradiol in mammary epithelial cells. RNA preparations from normal
(NMEC), transformed (HBL-100) and cancerous (MCF-7, MDA-MB-231) mammary epithelial cells were submitted to reverse tran-
scription and PCR ampli¢cation. RT-PCR assays were performed at 30 cycles (A) and at 40 cycles (B) of ampli¢cation. Lanes 1 rep-
resent the control experiment, lanes 2 the addition of 10ÿ8 M 17L-oestradiol and lanes 3 the simultaneous addition of 10ÿ8 M 17L-
oestradiol and 10ÿ6 M tamoxifen. FGF1 COD corresponds to total FGF1 reverse transcribed mRNAs and NR COD to nitrate reduc-
tase reverse transcripts added to the cellular RNA to ensure RT-PCR e⁄ciency remained constant in the di¡erent samples of each ex-
periment.
Fig. 4. ELISA analysis of FGF1 protein in cell extracts after
heparin-Sepharose chromatography. When NMEC, HBL-100,
MCF-7 and MDA-MB-231 cells reached about 50% con£uence,
they were cultured in phenol red-free and serum-free medium
for 48 h. Then the cells were treated by 10ÿ8 M 17L-oestradiol-
water soluble with or without 10ÿ6 M tamoxifen for 24 hours.
In the control experiment, the 17L-oestradiol was replaced by
sterile water and tamoxifen by absolute ethanol. Protein was
detected with anti-FGF1 polyclonal antibody in aliquots (100
Wl) of extracts of NMEC, HBL-100, MCF-7 and MDA-MB-
231 cells cultured in serum-free and phenol red-free medium
alone (0) or in presence of 10ÿ8 M 17L-oestradiol (E2) or of
10ÿ8 M 17L-oestradiol and 10ÿ6 M oestradiol inhibitor (I) ta-
moxifen (E2/I). Control wells coated with 2.5 ng of FGF1 in
100 Wl of PBS presented a mean value of OD at 490 nm of
2.07. Mean þ S.D. of triplicate determination (P6 0.05). Ex-
periments were repeated two times.
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1). At 30 cycles of PCR ampli¢cation, we observed
that addition of 1038 M 17L-oestradiol to phenol
red-free medium enhanced the transcription of cod-
ing FGF1 mRNAs in hormone-dependent NMEC
(Fig. 5A, lane 2 and Fig. 6, lane 2). No in£uence
of 17L-oestradiol on the transcription of coding
FGF1 mRNAs was detected either in a hormone-
sensitive HBL-100 cell line (Fig. 5A, lane 2) or in
the hormone-independent MDA-MB-231 cells (data
not shown). After 40 cycles of ampli¢cation, we did
not observe any change in FGF1 mRNA expression
when MCF-7 and MDA-MB-231 cells were treated
with 17L-oestradiol (Fig. 5B, lane 2). Simultaneous
treatment of NMEC, transformed HBL-100 cells or
of cancerous MCF-7 and MDA-MB-231 cells with
oestradiol and its receptor antagonist tamoxifen
(1036 M) had no e¡ect on coding FGF1 mRNA
transcription (Fig. 5 and 6, lanes 3).
One microgram of total RNA isolated from nor-
mal, transformed and cancerous cells was also sub-
mitted to RT-PCR to analyse 17L-oestradiol medi-
ated regulation of the four alternatively spliced
FGF1 transcripts (1.A, 1.B, 1.C and 1.D). At 30
cycles, the FGF1-1.A transcript was not detected in
any type of mammary cell studied here. No oestra-
diol modulation was observed on 1.C and 1.D tran-
scripts in NMEC, HBL-100 and MDA-MB-231 cell
lines (data not shown). These transcripts were not
detected in MCF-7 cells. Conversely, 17L-oestradiol
downregulated the 1.B transcript expression in
NMEC (Fig. 6, lane 2). In these cells, addition of
tamoxifen to oestradiol treatment induced the recov-
ery of the 1.B mRNA level obtained in the control
experiment (Fig. 6, lane 3).
4. Discussion
Our results demonstrate that NMEC, transformed
cells (HBL-100), cancerous MDA-MB-231 and
MCF-7 cells express FGF1 protein with an apparent
molecular mass close to 18 kDa. So it appears that
the endogenous FGF1 of all these cells has an appar-
ent molecular mass close to that of the FGF1 mol-
ecules we detected previously in the 500-fold concen-
trated MDA-MB-231 cell extract and in the serum-
free conditioned medium by these cells [41]. Accord-
ing to the immunodetection techniques used here,
normal cells, HBL-100 transformed cells and
MDA-MB-231 cancerous cells seem to express higher
levels of FGF1 compared to that of MCF-7 cells.
These results corroborate those obtained previously
on the expression of FGF1 mRNAs in normal,
transformed and cancerous breast epithelial cells
[37]. Indeed, NMEC, HBL-100 and MDA-MB-231
cells expressed similar high levels of FGF1 mRNAs
at 30 cycles of PCR ampli¢cation in semi-quantita-
tive assays, whereas 40 cycles were necessary to de-
tect FGF1 mRNAs in MCF-7 cells. FGF1 is also
present in the conditioned serum-free medium of
each of these cell types even in cells that are more
dependent upon serum and exogenous FGF than
MDA-MB-231 cells [26]. The proliferation of the
most invasive cancerous cell line MDA-MB-231 is
more notable than that of normal, transformed or
MCF-7 cancerous cells in serum-free medium. How-
ever, addition of neutralizing FGF1 antibody to se-
rum-free media induced a decrease of proliferation of
all the cells studied. This suggests that normal and
cancerous mammary epithelial cells are able to pro-
duce FGF1 and that this growth factor is implicated
in an external autocrine loop of growth stimulation.
Moreover, production of FGF2 and autostimulation
by this growth factor in MDA-MB-231 cells [41] may
contribute to explain the high proliferation level of
these cells and their independence toward exogenous
FGFs [26]. Although FGF1 [56,57] lacks a signal
peptide, it is clear that this growth factor is secreted
Fig. 6. RT-PCR analysis of FGF1 mRNA regulation by 17L-
oestradiol in normal mammary epithelial cells (NMEC). This
¢gure shows the regulation by 17L-oestradiol of total FGF1 co-
dant (FGF1 COD) and the alternative spliced FGF1 mRNA
containing the non coding exon B (FGF1.EB). NMEC were
maintained for 24 h in presence of 10ÿ8 M 17L-oestradiol alone
(lane 2) or with 10ÿ6 M tamoxifen (lane 3). The control was
performed as cells cultured in absence of 17L-oestradiol and ta-
moxifen (lane 1).
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from cells by an unknown mechanism, sequestered in
the extracellular matrix [58,59], and is released into
the culture medium. The di¡erent levels of prolifer-
ative response of normal, transformed and cancerous
cells to neutralizing anti-FGF1 antibody may be ex-
plained by di¡erential FGF1 production and/or
FGF1 receptor expressions on the cell surface. It
has been shown that heparan sulphate proteoglycans
(low a⁄nity receptors for FGF) play a dual role in
activating or inhibiting FGF mitogenic activity in
human breast cancer cells [32]. Particularly, MDA-
MB-231 and HBL-100 cells exhibit higher levels of
heparan sulphate proteoglycans than MCF-7 at the
cell surface [60], which might account for the di¡er-
ential sensitivity to FGF.
The growth of normal mammary epithelial cells is
regulated by growth factors and hormones [1]. How-
ever, the mechanism by which oestradiol acts on cell
proliferation is not completely known. Oestrogens
might stimulate directly cell proliferation through in-
teraction of its receptor with nucleotide sequences
regulating the expression of genes required for cell
multiplication [61,62]. Moreover, Migliaccio et al.
[63] demonstrated that the oestradiol-receptor com-
plex was able to activate the tyrosine kinase p21ras/
MAP-kinase pathway in the oestradiol-dependent
mammary cancer MCF-7 cells. It has also been
shown that oestrogens regulated EGF, TGFK, IGFII
and TGFL expression in breast cancer epithelial cells
[21^25] and so might in£uence indirectly the prolif-
eration of these cells. To date, nothing is known
about FGF1 regulation by oestrogens in normal
and cancer breast cells. In the present study, a
semi-quantitative assay based on PCR ampli¢cation
shows that in phenol red-free serum deprived me-
dium, NMEC, HBL-100 and MDA-MB-231 cells
contain an equivalently high level of FGF1 coding
mRNAs, while MCF-7 cells express a basal level of
these transcripts. We note that these RT-PCR results
are similar to those obtained previously [37] with
starved normal, transformed and cancerous cells
grown in the presence of phenol red, a substance
with a weak oestrogenic activity [64], and that they
corroborate the results obtained by immunodetection
of FGF1 protein. Otherwise, these results are consis-
tent with several reports on FGF1 production in
normal and human breast cancerous tissues [37^39].
Since oestrogens can stimulate indirectly the mam-
mary epithelial cell proliferation by enhancing
growth factor synthesis [21^23], we expected a higher
upregulation of FGF1 expression in MCF-7 cancer-
ous cells in comparison with normal cells. However,
as hormone-dependent MCF-7 cancer cells express
very low levels of FGF1 mRNAs in our experimental
conditions, it was di⁄cult to compare the oestradiol
regulation of these transcripts between normal and
cancerous cells. Nevertheless, ELISA demonstrated
an increase of FGF1 protein in MCF-7 cells in re-
sponse to 17L-oestradiol as it occurred in NMEC.
So, our results seem to indicate that the oestradiol
regulation of FGF1 protein is transcriptional in
NMEC and may be translational in MCF-7 and
HBL-100 cells. It was evident that the transcription
of FGF1 gene in MDA-MB-231 cells did not vary in
oestradiol assays since these hormone-independent
cells lack oestrogen receptors. This cell line was
used as a negative control in oestradiol assays. The
speci¢c action of oestradiol was veri¢ed using the
oestrogen receptor competitor, tamoxifen.
It has been reported that 5P and 3P non-coding
regions of several genes play a key role in the control
of protein production [65^69]. The 5P non-coding
region of human FGF1 gene may contribute to the
regulation of FGF1 protein translation. The analysis
of oestradiol regulation of the four alternatively
spliced FGF1 mRNAs (1.A, 1.B, 1.C and 1.D)
showed a decrease in the FGF-1.B transcript level
in normal cells but no change in other cells and no
change in the 1.C and 1.D transcript levels. We can
thus deduce that none of these four spliced mRNAs
are implicated in the increase of the total level of
FGF1 coding mRNAs in response to an oestradiol
stimulus in normal cells. This increase might be due
to one of the ¢ve spliced transcripts (1.AP, 1.AP/B,
1.AP/E, 1.AP/F, 1.AQ) recently described [44] or to
others yet to be discovered. The di¡erential expres-
sion [37] and the oestradiol regulation of the four
alternatively spliced FGF1 mRNAs in the normal
and malignant human mammary epithelial cells
might be key events in the control of FGF1 synthesis
and biological activity. It has been shown that tes-
tosterone increases the FGF1 mRNA level in hor-
mone-dependent DDT-1 tumour cells and that the
5P non-coding region of FGF1 gene contains DNA
elements responsive to testosterone [70]. By contrast,
the FGF2 gene does not respond to dihydrotestoster-
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one hormone in the context of human benign hyper-
plastic prostate [71]. However, oestrogen induces an
increase of FGF2 mRNA expression in the well dif-
ferentiated endometrial cancer cell line Ishikawa but
not in the undi¡erentiated ANC3CA cell line [72].
Moreover, FGF2 mRNA and protein levels are en-
hanced by follicle-stimulating hormone in Sertoli
cells of rat seminiferous tubule [73]. According to
these reports and to our results, the FGF1 and
FGF2 genes seem to be di¡erentially regulated by
hormones and in a cell-speci¢c manner.
In conclusion, our results demonstrate that both
normal, transformed and cancer mammary epithelial
cells are autostimulated to grow by FGF1 and that
17L-oestradiol participates in the regulation of FGF1
production in the oestrogen receptor-positive cells.
Further investigations with new identi¢ed spliced
transcripts will contribute to the understanding of
human FGF1 gene regulation. Moreover, our results
point out the potential interest in the development of
anti-hormonal and anti-growth factor chemothera-
pies in breast cancer.
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